Last reviewed · How we verify

NCT05263362: STARLINGS

An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study)

Completed Last updated 13 April 2026
What this trial tests

trial testing no intervention in Breast Fibrosis in 775 participants. Completed in 20 September 2024.

Timeline
11 April 2022
Primary endpoint
1 February 2024
20 September 2024

Quick facts

Lead sponsorErasmus Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment775
Start date11 April 2022
Primary completion1 February 2024
Estimated completion20 September 2024
Sites4 locations across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Erasmus Medical Center

Who can join

18 and older, female only, with Breast Fibrosis or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the role of different combinations of (oncoplastic) surgery and radiotherapy techniques as risk factors for moderate to severe fibrosis and for moderate to poor cosmetic outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other Erasmus Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05263362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing